Chaoju Eye Care Holdings Limited reported on 9 September 2026 that it repurchased 71,500 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 2.52 and HKD 2.58 per share, spending HKD 0.18 million. All repurchased shares are earmarked for cancellation.

Including this latest transaction, the company has accumulated 1.73 million shares for cancellation since 31 August 2026. The buybacks represent approximately 0.25% of Chaoju Eye Care’s current issued share capital of 701.46 million shares, which remains unchanged until the cancellation process is completed. The aggregate consideration for the 1.73 million shares amounts to about HKD 4.23 million, implying an average cost of roughly HKD 2.45 per share over the period.

The repurchases were executed under the general mandate approved on 12 May 2026, which authorises the company to buy back up to 70.52 million shares. To date, 5.07 million shares, or 0.72% of the share base at the mandate date, have been repurchased under this authorisation. In accordance with Hong Kong Listing Rules, Chaoju Eye Care is restricted from issuing new shares for 30 days following the latest repurchase, setting a moratorium period that ends on 9 October 2026.

All transactions were conducted on the Exchange and complied with Main Board Rule 10.06, with full board authorisation and confirmation that required regulatory filings have been completed.